Influence of a single oral dose of vitamin D₂ on serum 25-hydroxyvitamin D concentrations in tuberculosis patients

Authors: Martineau, A.R.¹; Nanzer, A.M.²; Satkunam, K.R.²; Packe, G.E.²; Rainbow, S.J.³; Maunsell, Z.J.³; Timms, P.M.⁴; Venton, T.R.⁴; Eldridge, S.M.⁵; Davidson, R.N.⁶; Wilkinson, R.J.⁷; Griffiths, C.J.⁵

Source: The International Journal of Tuberculosis and Lung Disease, Volume 13, Number 1, January 2009 , pp. 119-125(7)

Publisher: International Union Against Tuberculosis and Lung Disease

Buy & download fulltext article:

The full text is free.

View now:

PDF 335.7kb

Abstract:

SETTING: Newham Chest Clinic, London, UK.

OBJECTIVE: To determine the safety and efficacy of the administration of bolus-dose vitamin D₂ in elevating serum 25-hydroxyvitamin D (25[OH]D) concentrations in tuberculosis (TB) patients.

DESIGN: A multi-ethnic cohort of TB patients was randomised to receive a single oral dose of 2.5 mg vitamin D₂ (n = 11) or placebo (n = 14). Serum 25(OH)D and corrected calcium concentrations were determined at baseline and 1 week and 8 weeks post-dose, and compared to those of a multi-ethnic cohort of 56 healthy adults receiving an identical dose of vitamin D₂.

RESULTS: Hypovitaminosis D (serum 25[OH]D < 75nmol/l) was present in all patients at baseline. A single oral dose of 2.5 mg vitamin D2 corrected hypovitaminosis D in all patients in the intervention arm of the study at 1 week post-dose, and induced a 109.5 nmol/l mean increase in their serum 25(OH)D concentration. Hypovitaminosis D recurred in 10/11 patients at 8 weeks post-dose. No patient receiving vitamin D₂ experienced hypercalcaemia. Patients receiving 2.5 mg vitamin D₂ experienced a greater mean increase in serum 25(OH)D at 1 week post-dose than healthy adults receiving 2.5 mg vitamin D₂.

CONCLUSION: A single oral dose of 2.5 mg vitamin D₂ corrects hypovitaminosis D at 1 week but not at 8 weeks post-dose in TB patients.

Keywords: 25-hydroxyvitamin D; calcium; human; tuberculosis; vitamin D2

Document Type: Regular paper

Affiliations: 1: Centre for Health Sciences, Barts and The London School of Medicine and Dentistry, London, UK; Division of Medicine, Wright Fleming Institute, Imperial College, London, UK; National Institute for Medical Research, London, UK 2: Newham Chest Clinic, Forest Gate, London, UK 3: Department of Clinical Biochemistry, Northwick Park Hospital, Harrow, UK 4: Department of Chemical Pathology, Homerton University NHS Foundation Trust, London, UK 5: Centre for Health Sciences, Barts and The London School of Medicine and Dentistry, London, UK 6: Division of Medicine, Wright Fleming Institute, Imperial College, London, UK; Tuberculosis Clinic, Northwick Park Hospital, Harrow, London, UK 7: Division of Medicine, Wright Fleming Institute, Imperial College, London, UK; National Institute for Medical Research, London, UK; Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape T

Publication date: 2009-01-01

More about this publication?

The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
Editorial Board
Information for Authors
Subscribe to this Title
ingentaconnect is not responsible for the content or availability of external websites